In our study, 103 EGFR sensitive mutation NSCLC patients were divided into low HIF-1α group and high HIF-1α group according to the expression level of HIF-1α in NSCLC tissues before receiving EGFR-TKIs treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.